ALX Oncology Holdings Inc. (ALXO) is a Biotechnology company in the Healthcare sector, currently trading at $1.62. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is ALXO = $4 (+147.7% upside).
Valuation: ALXO trades at a trailing Price-to-Earnings (P/E) of -1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.07.
Net income is $102M (loss), growing at +3.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $5M against $26M equity (Debt-to-Equity (D/E) ratio 0.2, conservative). Current ratio is 2.07 (strong liquidity). Debt-to-assets is 8.8%. Total assets: $59M.
Analyst outlook: 6 / 7 analysts rate ALXO as buy (86%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 45/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).
